Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered question first ministerially corrected answering member label attachment file name title previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

820900

	registered interest
	date	11/01/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Chemotherapy: Standards
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many hospitals have met the national cancer waiting time standard for commencing chemotherapy treatment within 31 days of a clinical decision having been made in the latest period for which figures are available.
	tabling member constituency	Liverpool, Wavertree
	tabling member printed	Luciana Berger
	uin	122318
	answer	answer is ministerial correction date of answer 16/01/2018 answer text <p>132 out of 139 National Health Service trusts reporting activity in November 2017 (latest data available) met the 98% standard of delivering an anti-cancer drug regimen within one month of a decision to treat.</p><p> </p><p>NHS England publishes quarterly performance data on cancer waiting times standards, along with monthly provisional statistics which can be accessed at:</p><p><a href="https://www.england.nhs.uk/statistics/statistical-work-areas/cancer-waiting-times/" target="_blank">https://www.england.nhs.uk/statistics/statistical-work-areas/cancer-waiting-times/</a></p> answering member constituency Winchester answering member printed Steve Brine question first answered 16/01/2018 11:55:51 answering member 4067 label Biography information for Steve Brine
	tabling member	4036 label Biography information for Luciana Berger

748536

	registered interest
	date	05/07/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Police: Mental Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how many police forces in England operate a street triage scheme to support people with mental illness.
	tabling member constituency	Liverpool, Wavertree
	tabling member printed	Luciana Berger
	uin	3124
	answer	answer is ministerial correction date of answer 10/07/2017 answer text <p>38 out of 40 police forces in England have access to a Street Triage service – where mental health nurses accompany police officers on patrols, however, all forces have direct access to Mental Health Partners who provide advice and support them in dealing with the public.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 10/07/2017 16:37:27 answering member 4067 label Biography information for Steve Brine
	tabling member	4036 label Biography information for Luciana Berger

754717

	registered interest
	date	20/07/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Pharmacy
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what assessment his Department has made of the concentration of high street community pharmacies in different areas of the country; and if he will make a statement.
	tabling member constituency	Leicester South
	tabling member printed	Jonathan Ashworth
	uin	6408
	answer	answer is ministerial correction date of answer 11/09/2017 answer text <p>40% of community pharmacies are in a cluster where there are three or more pharmacies within ten minutes’ walk. As part of community pharmacy reforms, we have introduced a Pharmacy Access Scheme to protect pharmacies in areas where there are fewer pharmacies and higher health needs, and to ensure no residents in areas will be left without good access to a community pharmacy.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 11/09/2017 13:13:07 answering member 4067 label Biography information for Steve Brine
	tabling member	4244 label Biography information for Jonathan Ashworth

797514

	registered interest
	date	29/11/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Thyroid Gland: Diseases
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what medicines NHS England has approved for patients with thyroid conditions
	tabling member constituency	Southampton, Itchen
	tabling member printed	Royston Smith
	uin	116477
	answer	answer is ministerial correction date of answer 07/12/2017 answer text <p><del class="ministerial">For unbranded generics the Government relies on completion to keep prices down which generally works well and has led to low prices of these medicines. We alert the Competition and Markets Authority (CMA) when we believe that competition does not work. In the case of liothyronine, the CMA is currently investigating Concordia’s potential abuse of its dominant position to overcharge the National Health Service for liothyronine.</del></p><p> </p><p><del class="ministerial">In primary care community pharmacies are incentivised to source products at the lowest possible cost by allowing them to retain the medicines margin (the difference between what the NHS reimburses a pharmacy for a product and how much the pharmacy purchases it for) up to £800 million in England. In secondary care, competitive tenders ensure value-for-money to the NHS.</del></p><p><ins class="ministerial"> <p><ins class="ministerial">NHS England is not responsible for approving medicines. The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for ensuring that medicines and medical devices work and are acceptably safe. The National Institute for Health and Care Excellence makes recommendations for the National Health Service on whether medicines and other treatments represent a clinically and cost effective use of NHS resources.</ins></p><p><ins class="ministerial"><strong> </strong></ins></p><p><ins class="ministerial">A list of medicines licensed by the MHRA for the treatment of thyroid conditions is attached. The list is split into two sections because thyroid conditions can be split into either those associated with an overactive thyroid (hyperthyroidism), or an underactive thyroid (hypothyroidism). The list contains only those medicines licensed for overactive and underactive thyroid. It should be noted that not all of the medicines listed will be available on the market at any one time. </ins></p></ins></p> answering member constituency Winchester answering member printed Steve Brine question first answered 07/12/2017 15:27:25 question first ministerially corrected 07/12/2017 18:20:31 answering member 4067 label Biography information for Steve Brine attachment 1 file name 2017 12 06 Thyroid medicines formatted.xls title List of thyroid medicines previous answer version 27995 answering member constituency Winchester answering member printed Steve Brine answering member 4067 label Biography information for Steve Brine
	tabling member	4478 label Biography information for Royston Smith

748214

	registered interest
	date	04/07/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Carers
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, with reference to the Answer of 7 March 2017 to Question 66131, on carers, what plans he has to publish the national carers strategy.
	tabling member constituency	Worsley and Eccles South
	tabling member printed	Barbara Keeley
	uin	2923
	answer	answer is ministerial correction date of answer 10/07/2017 answer text <p><strong></strong>The Government remains committed to supporting carers to provide care as they would wish, and to do so in a way that supports their own health and wellbeing, employment and wider life chances.</p><p>We have said that more widely we will consult on proposals to improve social care. Next steps will be set out in due course.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 10/07/2017 16:31:40 answering member 4067 label Biography information for Steve Brine
	tabling member	1588 label Biography information for Barbara Keeley

780544

	registered interest
	date	30/10/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Prescriptions: Fees and Charges
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what estimate he has made of the cost per digital transaction of prescription prepayment certificates in October 2018.
	tabling member constituency	Hemsworth
	tabling member printed	Jon Trickett
	uin	110347
	answer	answer is ministerial correction date of answer 07/11/2017 answer text <p>A breakdown of the cost per digital transaction is unavailable.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 07/11/2017 17:17:27 answering member 4067 label Biography information for Steve Brine
	tabling member	410 label Biography information for Jon Trickett

790112

	registered interest
	date	15/11/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Antimicrobials: Drug Resistance
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what estimate his Department has made of the number of deaths by antimicrobial resistance in England in each of the last five years.
	tabling member constituency	Chipping Barnet
	tabling member printed	Theresa Villiers
	uin	113428
	answer	answer is ministerial correction date of answer 20/11/2017 answer text <p>A commonly quoted estimate for the number of deaths caused by an antimicrobial resistant (AMR) infection is 5,000 deaths in England each year.</p><p> </p><p>The estimate is also consistent with the Final Report and Recommendations from The Review on Antimicrobial Resistance, chaired by Jim O’Neill. The Review estimated the annual number of deaths caused by AMR infections worldwide to be of the order of 700,000. The report is available at:</p><p><a href="https://amr-review.org/sites/default/files/160525_Final%20paper_with%20cover.pdf" target="_blank">https://amr-review.org/sites/default/files/160525_Final%20paper_with%20cover.pdf</a></p> answering member constituency Winchester answering member printed Steve Brine question first answered 20/11/2017 17:10:13 answering member 4067 label Biography information for Steve Brine
	tabling member	1500 label Biography information for Theresa Villiers

800513

	registered interest
	date	04/12/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Breast Cancer: Biosimilar Medicines
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, whether NHS England has provided any guidance to hospital trusts and clinicians on the introduction of a biosimilar of Herceptin (trastuzumab) for breast cancer.
	tabling member constituency	West Ham
	tabling member printed	Lyn Brown
	uin	117134
	answer	answer is ministerial correction date of answer 12/12/2017 answer text <p>A final date for the availability of a biosimilar of Herceptin (trastuzumab) has yet to be agreed. Therefore NHS England has not yet issued any guidance on the introduction of a biosimilar of Herceptin (trastuzumab) for breast cancer. However, NHS England has discussed the introduction and uptake of biosimilar trastuzumab with the Cancer Vanguard. The Vanguard is a group of National Health Service trusts looking at developing new models of care and providing replicable models for cancer care nationally that will act as blueprints for the NHS.</p><p> </p><p>The Cancer Vanguard will provide guidance and supporting documentation to hospital trusts and clinicians in the same way that documents were provided to support the introduction of biosimilar rituximab. Once a firm date is known, NHS trusts will be contacted regarding the availability of biosimilar trastuzumab and what they must do to ensure uptake. This will include linkages to the supporting documents issued by the Vanguard.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 12/12/2017 17:11:26 answering member 4067 label Biography information for Steve Brine
	tabling member	1583 label Biography information for Ms Lyn Brown

772209

	registered interest
	date	17/10/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Multiple Sclerosis: Stem Cells
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what discussions his Department has had with clinical bodies on assistance with stem-cell therapy for people with MS.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	108227
	answer	answer is ministerial correction date of answer 25/10/2017 answer text <p>A form of stem-cell therapy “autologous haematopoietic stem cell therapy” is available on the National Health Service. It is a very aggressive treatment for relapsing-remitting multiple sclerosis (MS). It is available on the NHS in two centres in the United Kingdom: one in Sheffield and one in London. Further information can be found at the following link:</p><p><a href="http://www.sth.nhs.uk/autologous-haematopoietic-stem-cell-transplantation-for-multiple-sclerosis/" target="_blank">www.sth.nhs.uk/autologous-haematopoietic-stem-cell-transplantation-for-multiple-sclerosis/</a></p><p>In 2016, the National Institute for Health and Care Excellence (NICE), announced that it has been notified of the procedure “autologous un-manipulated peripheral blood stem cell therapy” for MS and consider it a part of the Institute’s work programme. The procedure is not currently being used outside of a research environment.</p><p> </p><p>The full NICE guidance for the diagnosis and management of MS can be found via the following link:</p><p><a href="http://www.nice.org.uk/guidance/cg186" target="_blank">www.nice.org.uk/guidance/cg186</a></p> answering member constituency Winchester answering member printed Steve Brine question first answered 25/10/2017 13:56:23 answering member 4067 label Biography information for Steve Brine
	tabling member	4131 label Biography information for Jim Shannon

819797

	registered interest
	date	10/01/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Medical Treatments: Innovation
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what plans his Department has to ensure a funding requirement is placed on medical technologies, devices and diagnostics that receive a positive technology appraisal from the National Institute for Health and Care Excellence.
	tabling member constituency	East Kilbride, Strathaven and Lesmahagow
	tabling member printed	Dr Lisa Cameron
	uin	121869
	answer	answer is ministerial correction date of answer 19/01/2018 answer text <p>A funding requirement automatically applies to any intervention, including medical technologies, devices and diagnostics, recommended in technology appraisal guidance issued by the National Institute for Health and Care Excellence, in line with the NHS Constitution.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 19/01/2018 11:29:37 answering member 4067 label Biography information for Steve Brine
	tabling member	4412 label Biography information for Dr Lisa Cameron